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The 2003 Congress of the European Society of Cardiology
(ESC) in Vienna, Austria, was attended by 25,463 people,
including 18,932 physicians. The program included 2,652
abstract presentations, 170 symposia or clinical seminars,
and 5 Hotline and Clinical Trial Update sessions. In this report
we review some of the key presentations. A detailed content,
including the abstracts, can be found in the Virtual Congress
Space on the ESC Website: http://www.escardio.org.
CLINICAL STUDIES
Treatment of chronic heart failure: a comparison of
carvedilol and metoprolol—COMET. The Carvedilol
Or Metoprolol European Trial (COMET) compares the
effects of carvedilol and metoprolol on mortality and mor-
bidity in patients with class II to IV chronic heart failure
and left ventricular (LV) ejection fraction (EF) 35% (1).
The study was presented by P. A. Poole-Wilson (London,
United Kingdom). A total of 3,029 patients were random-
ized and followed for a mean of 58 months. The primary
end points were all-cause mortality, and the composite end
point was all-cause mortality and all-cause hospital admis-
sion. A significant reduction occurred in all-cause mortality
with carvedilol as compared to metoprolol (34% vs. 40%, p
 0.0017). No significant difference existed between the
groups in the composite end point of all-cause mortality and
all-cause hospital admission. Therefore, the benefits of
carvedilol were driven by the reduction in mortality.
The doses used in COMET aimed for comparable
reductions in resting heart rate in the two groups. Initially,
heart rate decreased more in the carvedilol-treated than in
the metoprolol-treated patients, after four months by 13.3
beats/min in the carvedilol group and by 11.7 beats/min in
the metoprolol group. After 16 months, heart rates did not
differ.
Carvedilol was superior to metoprolol in this trial. How-
ever, the mechanism of the different responses to carvedilol
and metoprolol was not elucidated. Therefore, it is difficult
to exclude that a small difference in degree of beta-blockade
may play a role.
Treatment of chronic heart failure: cardiac resyncroniza-
tion therapy—COMPANION. The Comparison of
Medical Resyncronization, Pacing, and Defibrillation Ther-
apies in Heart Failure (COMPANION) trial investigates
whether patients with advanced heart failure and QRS
widening and who receive optimal pharmacological therapy
might benefit from one of two additional therapies, either
biventricular cardiac resyncronization therapy (CRT) alone
or biventricular CRT combined with cardioverter–
defibrillator therapy (CRT-ICD). The study was presented
by A. Feldman (Philadelphia, Pennsylvania). The primary
end points were time-to-first-event in terms of all-cause
death and all-cause hospitalization. The secondary end
points included all-cause mortality and morbidity. The main
findings were that CRT alone and CRT-ICD significantly
reduced the one-year event rate of the primary end point (by
19%), but only CRT-ICD significantly reduced the one-
year mortality rate (by 43%), whereas CRT alone was
associated with a nonsignificant trend to reduction in
one-year mortality. The significant difference in the com-
bined primary end point between optimal pharmacological
therapy and CRT groups was principally driven by all-cause
hospitalization.
Treatment of chronic heart failure: angiotensin receptor
blockade by candesartan—CHARM. The Candesartan in
Heart failure Assessment of Reduction in Mortality and
Morbidity (CHARM) program evaluated whether the an-
giotensin receptor blocker candesartan could reduce mortal-
ity and morbidity in patients with class II to IV chronic
heart failure. The program was made up of three random-
ized, double-blind, controlled clinical trials and included
7,601 patients. The results were presented by C. B. Granger
(Durham, North Carolina), J. J. V. McMurray (Glasgow,
United Kingdom), S. Yusuf (Hamilton, Ontario, Canada),
M. A. Pfeffer (Boston, Massachusetts), and K. Swedberg
(Gothenborg, Sweden). In the CHARM-Added trial, can-
desartan was added to treatment with angiotensin-
converting enzyme (ACE) inhibitors in patients with LV
EF 40%. In the CHARM-Alternative trial, candesartan
was given to patients not taking an ACE inhibitor owing to
intolerance to the drug. In the CHARM-Preserved trial,
effects of candesartan were studied in patients with chronic
heart failure and preserved EF (40%), the first large study
to include this group of patients.
When all three trials were considered together there was
a strong trend, of borderline significance (p  0.055),
toward a reduction in death from any cause (2). A signifi-
cant (p 0.012) reduction occurred in cardiovascular death,
from 20% in the placebo group to 18% in the candesartan
group.
Important adverse effects included an increase in serum
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potassium to 6.0 mmol/l or above in 2% of the candesartan-
treated patients as compared to 1% in the placebo group (p
 0.017). The average serum potassium increased by 0.14
mmol/l in the candesartan group, while there was no overall
change in the placebo group (p  0.0001). Creatinine
doubled in 6% of the candesartan-treated patients and in 4%
of the placebo-treated patients (p  0.002). Blood pressure
decreased more in the candesartan group, by 5.2 mm Hg in
systolic and by 3.0 mm Hg in diastolic pressure (p 0.001).
A small increase in fatal cancer likely resulted from the play
of chance. The incidence of nonfatal neoplasms detected
during the study was similar in the treatment groups.
Angioedema recurred in only 3 of 39 patients with previous
angioedema or anaphylaxis on ACE inhibitors. In these 3
patients the angioedema was mild and not life-threatening.
The CHARM-Added trial showed that in patients with
reduced EF, the addition of candesartan to an ACE
inhibitor caused a significant reduction in cardiovascular
death and hospital admission (3). Importantly, the benefits
of candesartan came on top of beta-blocker treatment.
The CHARM-Alternative trial showed that in patients
intolerant to ACE inhibitors, candesartan was well tolerated
and reduced cardiovascular mortality and morbidity (4). The
magnitude of the reductions was comparable to those
previously reported for ACE inhibitors. The CHARM-
Preserved trial showed no significant difference between the
candesartan and placebo groups in terms of cardiovascular
death (5). However, candesartan had a moderate positive
effect on hospital admissions.
The CHARM program provides strong support for the
use of angiotensin-receptor blockers in addition to ACE
inhibitors and beta-blockers in patients with chronic heart
failure and reduced EF, and as an alternative to ACE
inhibitors in patients with intolerance to the latter class of
drugs. However, higher rates of withdrawals for renal
dysfunction and hyperkalemia when an ACE inhibitor is
combined with angiotensin-receptor blockers indicate a
necessity for close monitoring of renal function and serum
potassium. There is also need for further studies in the
group of patients with heart failure and preserved EF, and
such studies should include objective measures of diastolic
function.
Treatment of stable coronary artery disease: ACE inhi-
bition by perindopril—EUROPA. The ACE inhibitors
have proved very effective therapy for hypertension and
heart failure. The Heart Outcomes Prevention Evaluation
(HOPE) trial established its benefits in patients at high risk
of cardiovascular events, including diabetics. This was
strongly suggestive of benefits beyond treatment of hyper-
tension or heart failure. The EURopean trial On reduction
of cardiac events with Perindopril in stable coronary Artery
disease (EUROPA) was presented by W. J. Remme
(Rhoon, The Netherlands) and K. Fox (London, United
Kingdom) (6). The study was established to test the ability
of perindopril to reduce cardiovascular death, myocardial
infarction (MI), and cardiac arrest in patients with stable
coronary artery disease (CAD) and without heart failure or
hypertension. A total of 13,655 subjects were registered
with either previous MI (64%), angiographic evidence of
CAD (61%), prior coronary revascularization (55%), or a
positive stress test only (5%). After a run-in period of four
weeks, patients were randomly assigned to either perindo-
pril (8 mg once daily) or matching placebo. At baseline,
more than 90% of the patients were on platelet inhibitors,
58% on lipid-lowering therapy, and 62% on beta-blockers.
After a mean follow-up of 4.2 years, patients randomly
assigned to perindopril had a 20% reduction of the com-
posite of cardiovascular death, nonfatal MI, and cardiac
arrest with successful resuscitation (from 9.9% to 8.0%, p 
0.0003). This benefit started to appear after one year and
gradually increased throughout the trial. This was associated
with a consistent benefit on secondary end points, notably
the composite of total mortality, nonfatal MI, unstable
angina, and cardiac arrest with successful resuscitation
(14.8% vs. 17.1%, p  0.0009). Most of the benefit
appeared to be driven by a reduction in fatal and nonfatal
MI. The clinical benefit was consistent in most predefined
subgroups, including men, women, elderly and young pa-
tients, diabetic patients, and patients with and without
hypertension. Importantly, the benefits were seen on top of
high usage of aspirin, beta-blockers, and lipid-lowering
drugs.
Treatment with perindopril was well tolerated, with 10%
of the patients who did not continue therapy after the
open-label run-in phase, and a similar withdrawal rate in
both treatment arms during the blinded treatment period.
The reduction in systolic blood pressure by perindopril was
on average 5.2 mm Hg. With respect to the primary end
point of the trial, approximately 50 patients must be treated
for four years to prevent one major cardiovascular event. It
was concluded that after EUROPA, strong consideration
should be given to adding the ACE inhibitor perindopril to
the standard therapy of all patients with stable CAD.
Treatment of acute MI: facilitated percutaneous coro-
nary intervention (PCI) with tenecteplase plus enoxa-
parin—GRACIA. Facilitated angioplasty refers to the
combination of primary angioplasty for acute MI preceded
by pharmacologic therapy “en route” to the catheterization
laboratory to facilitate intervention and specifically to
achieve recanalization in some patients prior to mechanical
intervention. To explore the value of such a strategy,
Spanish and Portuguese investigators in the Grupo de
Analisis de la Cardiopatia Isquemica Aguda (GRACIA)-2
trial randomized 212 patients in 15 centers with ST-
segment elevation acute MI to either a strategy of “facili-
tated intervention” (i.e., tenecteplase  enoxaparin, fol-
lowed within 3 to 12 h by revascularization using stents or
coronary artery bypass surgery) or to a strategy of optimal
primary PCI of the infarct-related artery, using stents and
abciximab. The end points of the trial were three-fold: 1)
infarct size measured by c-troponinT and creatine
kinase-MB mass release; 2) the percentage of patients with
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ST-segment resolution at 1, 3, and 6 h; 3) LV EF and
volumes at six weeks. F. F. Aviles (Valladolid, Spain)
presented results on behalf of the GRACIA group. No
significant difference existed between groups in terms of
infarct size measured by biomarker release, but there was a
trend toward smaller infarcts in the facilitated group. There
was a similar percentage of patients in both groups with
complete ST-segment normalization at 1 and 3 h. However,
6 h after treatment, 61% of the patients in the facilitated
intervention group as compared to 43% in the optimal
primary PCI group had complete resolution (p 0.03). The
LV EF volumes, and wall motion index measured at six
weeks were not different between groups. There was no
difference in cardiac events and major bleeding between
groups, although there were trends toward lower mortality
at six weeks (3% vs. 6%) and lower rate of severe bleeding
(2% vs. 3%). The investigators concluded that this study
suggests that both strategies are similarly effective in restor-
ing patency, limiting infarct size, and preserving LV func-
tion. If this equivalence is confirmed in larger studies, it may
result in an increase in the proportion of patients who would
get access to angioplasty, as facilitated PCI prolongs the
time window for mechanical intervention. The discussant of
this trial, F. Van de Werf (Leuven, Belgium), commented
that the results of this study are in support of the concept of
a combined pharmacological–mechanical approach to pa-
tients with ST-segment elevation MI and are in agreement
with the observations made in Comparison of Angioplasty
and Prehospital Thrombolysis in Acute Myocardial Infarc-
tion (CAPTIM). Whether this approach should be gener-
alized and which pharmacological therapy should be pre-
ferred are the topics of ongoing large trials such as
Facilitated Intervention with Enhanced Repercussion Speed
to Stop Events (FINESSE), Combined Abciximab REte-
plase Stent Study in Acute Myocardial Infarction
(CARESSE), and Assessment of the Safety and Efficacy of
a New Thrombolytic (ASSENT-4).
Treatment of acute MI: facilitated PCI with tirofiban—
ON-TIME. Primary angioplasty is increasingly used as
reperfusion therapy for ST-segment elevation MI. In these
patients with acute coronary thrombosis, glycoprotein (GP)
IIb/IIIa blockers are intuitively rational drugs to use as an
adjunct to PCI, yet clinical trials have provided conflicting
results regarding the value of these agents, possibly because
they need to be used for some time before the intervention
to provide optimal benefit. Because a substantial fraction of
patients with ST-segment elevation MI are diagnosed in the
prehospital setting or need transfer from a noninterven-
tional site to an interventional laboratory, it is logical to test
the value of a GP IIb/IIIa blocker “upstream” of PCI in this
patient subset.
Dutch investigators coordinated this trial, presented by
A. W. J. Vant’Hof (Zwolle, The Netherlands), which
compared early initiation of tirofiban therapy versus initia-
tion in the catheterization laboratory in acute MI patients
who are candidates for primary PCI. The primary end point
of the trial was the Thrombolysis In Myocardial Infarction
(TIMI) flow grade 3 at initial angiography, as it was hoped
that prehospital administration might result in a higher
patency rate before PCI, which in turn is usually correlated
with higher success rates for primary mechanical interven-
tion and improved clinical outcomes. Secondary end points
included TIMI flow in the infarct-related vessel, presence of
thrombus in the infarct artery at initial angiography, and
success rates for primary PCI. Approximately 500 patients
were randomized to early versus late initiation of tirofiban.
All patients received unfractionated heparin (5,000 IU) and
aspirin (500 mg IV bolus) before PCI. After PCI, all
patients were treated with weight-adjusted low molecular
weight heparin for 48 h, clopidogrel 300 mg loading and 75
mg for 30 days, and aspirin, beta-blocker, ACE inhibitors,
and statins. Tirofiban was given as a first bolus of 10 g/kg,
followed by a 0.15 g/kg/min infusion lasting 24 h. Females
younger than 50, and all patients older than 80 years, or in
Killip class III or IV, or on treatment with oral anticoagu-
lation, or treated with fibrinolysis24 h, in hemodialysis, or
with contraindications to the use of GP IIb/IIIa inhibitors
were not included. After randomization (41% in the ambu-
lance) patients were immediately taken to a PCI center
rather than to the nearest hospital. Mean age was 62 years;
10% of patients were diabetics, 46% had anterior infarction,
and 16% were in Killip class 2.
Patient-related delay was 94 min, and the time from
diagnosis to randomization was 25 min. Interhospital trans-
portation required 33 min, the door-to-angiography time
was 25 min, and finally the time from angiography to
angioplasty was 15 min. The early group received initiation
of tirofiban in non-PCI centers (51%), in the prehospital
setting (41%), or in the emergency room of a PCI center
(8%) before going to the catheterization laboratory. The
median difference in delay to tirofiban administration be-
tween the two treatment arms was 59 min. On initial
angiography, assessed by a central core laboratory, TIMI
flow grade 3 in the infarct vessel was seen in 19% versus 15%
of the early and late patients, respectively (p  0.22), and
combined TIMI flow grade 2 or 3 in 43% versus 34% (p 
0.04). Thrombus was seen in 25% versus 32% of the infarct
vessels in the early and late groups and fresh occlusion in
35% versus 41% (p  0.20). The combined incidence of
thrombus and fresh occlusion was seen overall in 60% versus
73% (p  0.002). There was no difference as to the final
PCI result: TIMI flow grade 3 was 89% in the early group
versus 91% in the late group (p  0.56), myocardial blush
grade 3: 51% versus 53% (p  0.87), and corrected TIMI
frame count 27 17 versus 26 15 (p 0.56). At 30 days,
11 patients died (2.2%) and only 5 had reinfarction (1%); 1
patient had fibrinolysis-related stroke and 19 had major
bleeding (3.7%).
Thus, the ON-TIME trial showed a modest improve-
ment in patency rates with prehospital initiation of tirofiban
prior to primary PCI, compared to catheterization labora-
tory initiation. There was a borderline reduction in angio-
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graphic evidence of thrombus. Given the relative safety of
this therapy, it deserves further study for early “facilitation”
of primary PCI on top of heparin and aspirin in patients
with acute MI transferred to undergo mechanical reperfu-
sion therapy. The study discussant, F. Ribichini (Novara,
Italy), commented that ON-TIME shows that the optimal
medical treatment to facilitate PCI in ST-segment elevation
MI is still not defined. The TIMI flow grade 3 reported by
the investigators is similar to that obtained with the pre-
PCI administration of abciximab in the Abciximab before
Direct angioplasty and stenting in Myocardial Infarction
Regarding Acute and Long-term follow-up (ADMIRAL)
trial (17%), and lower than the TIMI flow grade 3 rate
obtained with a half dose of tissue-type plasminogen acti-
vator (t-PA) in the Plasminogen activator Angioplasty
Compatibility Trial (PACT) (33%).
The most remarkable finding of ON-TIME is not related
to the study drug, but to the very short time of patient-delay
and health-care system reaction. Indeed, patient-related
delay is almost half of that seen in the Global Utilization of
Streptokinase and tPA for Occluded Arteries (GUSTO) V
trial, and door-to-balloon time is 50 min. This indicates
that pretreatment times can be largely reduced, and this
is expected to translate into clinical benefit. Enhancing the
awareness of patients about the significance of symptoms
and the health-care network about the importance of
shortening intervention times will likely maximize the
mortality benefit eventually obtainable with any therapy.
PCI after MI: effect of late recanalization—DECOPI.
The value of late recanalization of the occluded infarct
artery remains both unsettled and a controversial topic.
Though a host of experimental and observational clinical
data exist to suggest the benefit of late recanalization of the
infarct artery beyond the time window compatible with
myocardial salvage (the “open artery hypothesis”), current
evidence from randomized clinical trials is still scarce and
inconsistent. In fact, the latest trial even suggested potential
harm from late recanalization of the infarct vessel. The
DEsobstruction COronaire Post Infarctus (DECOPI) trial
is a French and Belgian study, presented by P. G. Steg
(Paris, France), which randomized 212 patients with TIMI
flow grade 0/1 in the infarct artery on angiography per-
formed 2 to 15 days after infarct onset to either angioplasty
or standard medical therapy. All patients received optimal
medical care, and angiography was repeated at six months.
The primary end point of the trial was the combination of
cardiovascular death, nonfatal MI, and severe ventricular
tachyarrhythmias. After an average of 34 months of follow-
up, the comparison between the two strategies shows no
difference in the primary end point (8.7% in the medical
group; 7.3% in the PCI group, p  0.64). There were also
no differences between groups in the rates of death, MI,
ventricular arrhythmias, admission for heart failure, admis-
sion for cardiac causes, revascularization, or ischemia at
six-month stress test. Because of spontaneous recanalization
on one hand and reocclusions on the other, at six months,
patency of the infarct artery was seen in 39.7% of the
patients in the medical arm and 82.7% of patients in the
angioplasty arm (p  0.0001). Importantly, there was a
47.1% restenosis rate in the angioplasty arm. At six months,
angiographic LV EF was superior by approximately 3.5% in
the angioplasty arm (p  0.025). Functional status at the
end of the trial (dyspnea and angina) was comparable
between groups. Costs were higher in the angioplasty arm (€
13,484 vs. € 12,468, p  0.0001). This amounts to $17,101
and $15,813 USD, respectively, assuming 1 Euro 
$1.2629 USD. Overall, the event rates in this population
were low, and there was no obvious clinical benefit to
systematic angioplasty of the infarct-related vessel.
Although PCI was associated with a higher LV EF at six
months and a higher coronary patency rate, this did not
translate into statistically significant differences in outcomes,
at the expense of higher costs. Because these results were
observed in a small population at relatively low risk, care
should be exercised before generalizing these conclusions.
Whether a strategy of angioplasty would be beneficial in a
higher-risk population is currently being tested in a large-
scale international trial, the Open Artery Trial (OAT). The
study discussant, E. Braunwald (Boston, Massachusetts),
noted that, while this was the largest trial to date, and the
first one to use modern therapy including stents, it ad-
dressed a low-risk patient population and was underpow-
ered. Therefore, the investigator concluded that the “open
artery hypothesis” was still alive and well and that it was
necessary to await results of the large-scale OAT trial,
performed in high-risk patients, for definitive conclusions.
Secondary prophylaxis after MI: oral direct thrombin
inhibition with ximelagatran—ESTEEM. The Efficacy
and Safety of the oral direct Thrombin inhibitor ximElagatran
in patients with rEcent Myocardial damage (ESTEEM) trial
investigated the efficacy and safety of the oral direct throm-
bin inhibitor ximelagatran in patients with recent myocar-
dial damage (7). The results were presented by L. Wallentin
(Uppsala, Sweden). This was a placebo-controlled, double-
blind trial in 1,883 patients who underwent recent ST-
elevation or non–ST-elevation MI. Either ximelagatran in
different doses or a placebo was given for six months, both
on top of acetylsalicylic acid. The primary outcome was the
composite of death, nonfatal MI, and severe recurrent
ischemia. Ximelagatran significantly reduced the primary
end point from 16.3% to 12.7% (p  0.036). The frequency
of major bleeds did not differ between the groups. However,
the cumulative risk of bleeding, both major and minor, was
higher in the ximelagatran group than in the placebo group.
Ximelagatran was associated with a rise in liver enzyme
concentrations. It was concluded that oral direct thrombin
inhibition with ximelagatran and acetylsalicylic acid is more
effective than acetylsalicylic acid alone in preventing major
cardiovascular events during six months of treatment in
patients who have had a recent MI. Further trials are
needed, including studies on safety aspects, to define the
role of ximelagatran in this patient population.
694 Smiseth et al. JACC Vol. 43, No. 4, 2004
ESC Congress 2003 February 18, 2004:691–7
Treatment of multivessel coronary disease: PCI or
CABG—GABI. The German Angioplasty Bypass sur-
gery Investigation (GABI) trial was a German multicenter
study comparing PCI and coronary artery bypass graft
(CABG) surgery in patients with multivessel coronary
disease. The original results were published in 1994, show-
ing that PCI and CABG as initial treatments resulted in
equivalent improvement in angina after one year. How-
ever, patients treated with PCI were more likely to require
further interventions and antianginal drugs, whereas pa-
tients treated with CABG were more likely to sustain an
acute MI at the time of the procedure. J. Kaehler (Ham-
burg, Germany) presented the long-term follow-up of that
trial. After 10 years of follow-up, no difference was seen in
the rate of cardiac deaths between the two arms. Reinter-
ventions were slightly, albeit nonsignificantly, more fre-
quent in the angioplasty arm than in the surgery arm
(139 vs. 97; p  NS), but the time frame for the need of
repeat revascularization was strikingly different between
groups: during the first year, reinterventions were clearly
more frequent in the angioplasty arm (p  0.001); thereaf-
ter, it was the reverse (p  0.004).
NEWS FROM BASIC RESEARCH
Cardiac remodeling: mechanisms. In the area of basic
research, a major focus was on cardiac remodeling and
approaches to reverse remodeling. “Remodeling” originally
described the alterations in LV shape and function that
follow MI. The use of the term has since expanded
considerably, and remodeling is now commonly used to
describe changes in morphology and function at the cellular
and molecular level, in particular with cardiac hypertrophy
and cardiac failure. Hypertrophy of the cardiac myocyte
occurs in response to mechanical and neurohormonal stim-
uli and is accompanied by functional remodeling resulting
from altered expression and regulation of a large number of
genes. Although hypertrophy has been linked to reexpres-
sion of a fetal gene program, it is clear that the phenotype
(e.g., the contractile or electrical function) can vary depend-
ing on the stimulus. Both DNA microarrays and proteomic
analysis offer a novel approach to explore the underlying
mechanisms.
In Vienna, several studies were presented confirming
different expression patterns in studies of human biopsies
with different etiology of heart failure (8), and in compari-
son of different animal models for hypertrophy (9). An
important complementary approach is functional analysis at
the cellular and subcellular levels to evaluate and interpret
findings at the protein level. Studies investigating the
changes in sarcoplasmic reticulum function in models of
cardiac hypertrophy and heart failure reported alterations in
phosphorylation status of calcium transporters (10,11) and
opposite responses of SERCA expression to volume or
pressure overload (12). These studies illustrate that various
mechanisms can be involved and that we should not
oversimplify our view of the phenotype of the cardiac
myocyte in the hypertrophied or failing heart.
A major mechanism underlying this diversity may be the
activation of different signaling pathways. The signaling
cascades leading to cardiac cell growth or hypertrophy are
diverse and complex, with several links to the apoptosis
pathways. An interesting pathway currently under investi-
gation is the PI3K/Akt pathway, which is believed to lead to
cellular hypertrophy with preserved or even supernormal
function. Further evidence was presented that this might
also be the pathway for the so-called physiological hyper-
trophy during exercise (13). Activation of this pathway
could theoretically be called upon to improve contractile
function, and data were presented on the anti-apoptotic
effect of this pathway (14). Novel links to hypertrophy and
remodeling currently under investigation are the cell-cycle
regulatory proteins that were shown to be activated by
hypertrophic stimuli (15). The apoptotic pathways could
also be a novel target to influence postinfarction remodeling.
It was reported that constitutive block of these pathways in
transgenic mice have a positive effect on cardiac morphology
and function after induction of MI (16). The p38/MAPK
pathways are also activated following MI and could con-
tribute to hypertrophy as well as apoptosis. A novel study
(17) has linked this pathway to fibrosis and showed that
blocking this pathway could reduce fibrosis following in-
farction.
Stem cells and enhanced angiogenesis in the treatment of
heart disease. Although several clinical trials are currently
investigating whether infusion of stem cells, bone-marrow
derived or endothelial progenitor cells, in the infarct area
improves cardiac function (18), the basic question of
whether these cells will eventually form cardiomyocytes in
situ and contribute to contraction remains unanswered.
Several studies presented in Vienna addressed this issue,
looking at differentiation in vitro using different culture
techniques (19–21) and/or phenotyping of cells after injec-
tion in animal models (22–24). These reports should be
viewed with cautious optimism; several markers for cardio-
myocytes are present, but a full adult ventricular cell
phenotype has not yet been reported. In the in vitro
conditions, cells appear to remain in the neonatal stage in
terms of electrical characteristics and excitation–contraction
coupling. This may be related to the lack of interaction with
adult myocytes, the lack of appropriate loading conditions,
and/or of humoral factors, and is reminiscent of the phe-
notype adopted by isolated adult ventricular myocytes in
long-term culture. The presentations reminded us that more
experimental studies are needed to establish the relationship
between cell therapy and specific functional improvement.
Although positive results are reported (25), very different
regimens are used, and the optimal timing, dose, cell type,
and mechanism of action of cell therapy remain
undetermined.
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As an alternative to cell transplantation, several studies
looked for activation of endogenous progenitor cells. Such
activation can be demonstrated (22,26–28), but it remains
unclear whether this would eventually lead to a significant
increase in the number of functional cardiomyocytes.
The increased angiogenesis induced and mediated by the
injected stem cells may be an alternative mechanism leading
to improved cardiac function (22). Improving perfusion by
enhanced angio- and arteriogenesis was another important
theme. A novel function was reported for the adipocytokine
leptin, which was shown to stimulate collateral formation in
a hindlimb model of ischemia (29). The same group further
investigated signaling pathways for arteriogenesis and dem-
onstrated a central role for CD44 as arteriogenesis was
significantly reduced in CD44 knockout mice (30). The
clinical perspective was illustrated by the association of poor
collateralization in patients with low levels of expression of
CD44.
Electrophysiology: new insights. In the area of electro-
physiology, several studies reported on modulation of nor-
mal and abnormal automaticity. The pacemaker current If,
normally present in the sinoatrial node cells, is encoded by
the HCN gene. In the heart isoforms, HCN1, HCN2, and
HCN4 are expressed, with a predominance of HCN4 in the
sinoatrial node and no or extremely low levels of expression
in the ventricle of the HCN2 isoform. Ectopic expression of
HCN2 in the atrium induces pacemaker activity, an ap-
proach with potential to treat sinus node dysfunction, as
presented by M. Rosen (New York, New York) (31).
During cardiac remodeling and hypertrophy the expression
of HCN in ventricular cells can increase and potentially
contribute to arrhythmias. In Vienna a study was presented
that links increased expression of HCN2 to abnormal
automaticity in endothelin-induced hypertrophy of adult
ventricular myocytes (32).
The relation between calcium handling and pacemaker
activity is currently another area under intense research.
Spontaneous sarcoplasmic reticulum calcium release events
contribute to the normal diastolic depolarization process in
the sinoatrial node, even though their relative importance
remains a matter of debate, as addressed by D. Di Francesco
(Milan, Italy) and D. A. Terrar (Oxford, United Kingdom).
Atrial myocytes isolated from patients with atrial dilation
showed a higher incidence of spontaneous release events,
which could potentially contribute to arrhythmogenesis and
atrial fibrillation (33). Finally, altered calcium handling was
also proposed to be at the basis of an increased propensity
for atrial fibrillation in mice with a deficiency of Annexin-7
(34).
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